Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 200

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 200
---
 g. | Property and equipment, net: |

Property and
equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated
useful lives of the assets at the following rates:

|                                    |     | % |    |
| Computers and electronic equipment |     |   | 33 |

| h. | Impairment of long-lived assets: |

The Company’s
long-lived assets are reviewed for impairment in accordance with Accounting Standards Codification (“ASC”) 360, “Property,
Plant and Equipment”. Whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted
cash flows expected to be generated by the assets. If such asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds its fair value.

<div align='center'>F-11</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Assets to be
disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During the years ended December 31, 2024
no impairment losses have been identified.

| i. | Research and development expenses: |

Research and
development expenses are charged to the statement of comprehensive loss as incurred.

In-Process
Research and Development assets, acquired in an asset acquisition (i.e., assets acquired outside a business combination transactions)
that are to be used in a research and development project which are determined not to have an alternative future use are charged to expense
at the acquisition date in accordance with ASC 730, “Research and Development”.

| j. | Severance pay: |

The subsidiary’s
liability for severance pay is subject to Section 14 of Israel’s the Severance Compensation Act, 1963 (“Section 14”),
pursuant to which all Subsidiary’s employees are included under Section 14, and are entitled only to monthly deposits, at a rate
of 8.33% of their monthly salary, made in the employee’s name with insurance companies. Under Israeli employment law, payments in
accordance with Section 14 release the subsidiary from any future severance payments